Skip to main content

#153716

NUCOLL43 Cell Line

Cat. #153716

NUCOLL43 Cell Line

Cat. #: 153716

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Availability: 8-10 weeks

Organism: Human

Tissue: Ovary

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Nicola Curtin

Institute: Northern Institute For Cancer Research, Newcastle University

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: NUCOLL43 Cell Line
  • Alternate name: O-CCC, ovarian clear cell carcinoma, HGSC, high grade ovarian cancer, TP53, CA125, LOH, loss of heterozygosity
  • Cancer: Gynaecologic cancer
  • Cancers detailed: Ovarian clear cell carcinoma
  • Research fields: Cancer;Cell biology;Genetics
  • Tool sub type: Primary
  • Parental cell: Clear cell adenocarcinoma of gynecological origin
  • Organism: Human
  • Gender: Female
  • Tissue: Ovary
  • Disease: Cancer
  • Growth properties: Doubling time approximately 45 hours
  • Model: Cancer Model
  • Conditional: No
  • Description: Ovarian cancer is a significant cause of death in women worldwide with the majority of ovarian cancers forming in women under the age of 65. Due to late stage diagnosis and a lack of reliable screening tests, survival rates after 5 years are below 50% in developing counties. Ovarian cancer can spread to tissues in close proximity to the ovaries, including the lining of the abdomen, lungs, lymph nodes and liver. Ovarian cancer has a number of histological subtypes and ovarian clear cell carcinomas generally respond poorly to chemotherapy. NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation. Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics. NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the genome.NUCOLL43 cells are resistant to cisplatin and rucaparib, but sensitive to paclitaxel, camptothecin and NVP-BEZ 235.
  • Biosafety level: 1

Applications

  • Application notes: NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation. Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics. NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the...

Handling

  • Format: Frozen
  • Growth medium: RPMI-1640 media supplemented with 20% FBS and cultured at 37?‚°C in 5% CO2.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Franklin et al. 2018. Cancer Med. :. PMID: 30109783.
  • Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.